Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

2.65

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.79

EPS Last/This Y

EPS This/Next Y

4.07

Price

4.36

Target Price

5

Analyst Recom

3

Performance Q

25.65

Relative Volume

Beta

0.9

Ticker: ADVM




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-17ADVM4.261.320.9018454
2025-11-18ADVM4.251.310.2518510
2025-11-19ADVM4.241.30999.9918580
2025-11-20ADVM4.21.300.8318592
2025-11-21ADVM4.141.3118.8418677
2025-11-24ADVM4.121.409.8014155
2025-11-25ADVM4.091.5422.3115322
2025-11-26ADVM4.161.7137.7516458
2025-12-01ADVM4.21.882.3717936
2025-12-02ADVM4.161.8948.2318345
2025-12-03ADVM4.172.024.9019109
2025-12-04ADVM4.182.0217.8819113
2025-12-05ADVM4.262.1121.3619130
2025-12-08ADVM4.382.240.6419361
2025-12-09ADVM4.362.240.6119361
2025-12-10ADVM4.362.240.6119361
2025-12-11ADVM4.362.240.6119361
2025-12-12ADVM4.362.240.6119361
2025-12-15ADVM4.362.240.6119361
2025-12-16ADVM4.36N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-17ADVM4.2772.9-42.4-7.68
2025-11-18ADVM4.2672.9-29.5-7.68
2025-11-19ADVM4.2572.9-29.7-7.68
2025-11-20ADVM4.2072.9-27.7-7.68
2025-11-21ADVM4.1416.6-27.8-8.23
2025-11-24ADVM4.1116.6-28.2-8.23
2025-11-25ADVM4.0916.6-27.7-8.23
2025-11-26ADVM4.1616.6-31.9-8.23
2025-12-01ADVM4.2016.6-31.1-8.23
2025-12-02ADVM4.1616.6-27.5-8.23
2025-12-03ADVM4.1716.6-29.2-8.23
2025-12-04ADVM4.1816.6-30.3-8.23
2025-12-05ADVM4.2616.6-32.8-8.23
2025-12-08ADVM4.3616.6- -8.23
2025-12-09ADVM0.0016.6103.1-8.23
2025-12-10ADVM4.3616.6-29.7-8.23
2025-12-11ADVM4.3616.6-29.7-8.23
2025-12-12ADVM4.3616.6-29.7-8.23
2025-12-15ADVM4.3616.6-29.7-8.23
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-17ADVM0.004.196.72
2025-11-18ADVM0.004.196.72
2025-11-19ADVM0.004.196.72
2025-11-20ADVM0.004.196.72
2025-11-21ADVM0.004.196.72
2025-11-24ADVM0.00-5.007.14
2025-11-25ADVM0.00-5.007.14
2025-11-26ADVM0.00-5.005.90
2025-12-01ADVM0.00-4.995.90
2025-12-02ADVM0.00-4.995.90
2025-12-03ADVM0.00-4.995.90
2025-12-04ADVM-6.47-4.995.90
2025-12-05ADVM-6.47-4.997.09
2025-12-08ADVM-9.37-4.997.09
2025-12-09ADVM-7.97-4.997.09
2025-12-10ADVM-7.96-4.993.81
2025-12-11ADVM-7.96-4.993.81
2025-12-12ADVM-7.96-4.993.81
2025-12-15ADVM-7.9602.65
2025-12-16ADVM-14.0802.65
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="ADVM" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-2.03

Avg. EPS Est. Current Quarter

-1.64

Avg. EPS Est. Next Quarter

-1.24

Insider Transactions

-14.08

Institutional Transactions

Beta

0.9

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

1

Growth Score

19

Sentiment Score

65

Actual DrawDown %

97.1

Max Drawdown 5-Year %

-98.6

Target Price

5

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

-8.57

Average EPS Est. Cur. Y​

-8.23

EPS Next Y. (Est.)

-4.16

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

305

Return on Equity vs Industry %

320.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-2.53

EBIT Estimation

-29.7
[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”ADVM” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ADVM” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ADVM” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ADVM” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ADVM” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ADVM” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ADVM” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Adverum Biotechnologies, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 155
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
stock quote shares ADVM – Adverum Biotechnologies, Inc. Stock Price stock today
news today ADVM – Adverum Biotechnologies, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ADVM – Adverum Biotechnologies, Inc. yahoo finance google finance
stock history ADVM – Adverum Biotechnologies, Inc. invest stock market
stock prices ADVM premarket after hours
ticker ADVM fair value insiders trading